ForDoz Pharma has entered into an agreement with Lupin, to market and distribute two complex injectable products in advanced development stage at ForDoz, in the U.S. and its territories. The products are in the oncology and anti-infective therapeutic areas which when approved, will provide affordable alternatives to patients and healthcare professionals.
 
These two licensed products are flagship technology assets among ForDoz’ complex injectable product pipeline portfolio including, liposome, microsphere, emulsion, nanocrystal, control release nanosuspension, and micelle. ForDoz is responsible for developing and obtaining necessary regulatory approvals. The products will be manufactured in ForDoz Pharma’s U.S.-based manufacturing site. Lupin is responsible for commercialization of the products. The deal terms are confidential.
 
“ForDoz Pharma is excited to partner our flagship products with Lupin,” said James He, founder and chief executive officer, ForDoz. “Lupin’s leadership presence in the U.S. will complement ForDoz’s scientific capability to bring affordable medicines to patients in an efficient manner.”
 
Alok Sonig, chief executive officer, US generics and global head, generics R&D and biosimilars at Lupin, said, “The partnered assets are a key, strategic addition to our complex injectables pipeline, and will bolster our institutional business offerings. These assets will complement Lupin’s ongoing organic R&D efforts in complex assets including inhalation and long-acting injectables as well as biosimilars.”